GSK stock plunged Wednesday after sales of its RSV vaccine, Arexvy, skidded and widely missed Wall Street's expectations.

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker was hit by issues with access to the shots in the US.

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GlaxoSmithKline ( (GSK) ) has realeased its Q3 earnings. Here is a breakdown of the information GlaxoSmithKline presented to its investors.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...